



FOR IMMEDIATE RELEASE

**Patients Enrollment completed in Clinical Study on
Propionyl-L-Carnitine Tablets for treatment of Peripheral Arterial Diseases**

Hong Kong, July 2, 2010—Lee's Pharmaceutical Holdings Limited (Main Broad Stock: 950: Website: www.leespharm.com) today announced that the Group has successfully reached the targeted patient enrollment for its clinical trial conducted in China on Sigma-Tau's original product, **Dromos**[®] (Propionyl-L-Carnitine hydrochloride tablets, "PLC"), evaluating the effectiveness and safety for treatment of peripheral arterial diseases (intermittent claudication) in Chinese patients.

This multi-centers, randomized, double-blind and placebo controlled clinical trial was conducted over 9 clinical centers located in Beijing, Shanghai, Tianjin, Nanjing and Wuhan etc; and led by Xuanwu Hospital of Capital Medical University. The trial has completed its targeted enrollment with total of 239 patients and completion of follow-up is expected in 4 months.

"We are pleased to have reached this important milestone in the PLC study. We would like to thank the dedicated clinical investigators, study coordinators, patients and our clinical development team who participated in our trial as well as the support from Sigma-Tau Group," said Dr. Benjamin Li, the Chief Executive Officer of the Company. "We are very excited about the progress of this study, and we look forward to the successful registration of PLC in China."

Propionyl-L-carnitine is a short-chain fatty ester of carnitine and a naturally occurring substance required in mammalian energy metabolism. The mechanisms by which supervised physical training improves walking ability in patients with intermittent claudication are microcirculatory, rheological, and metabolic. The main mechanism of levo propionyl carnitien is metabolic; it increases the walking ability in claudicants, providing an additional energy to the ischemic muscle by an anaplerotic activity.

With the completion of enrollment, the Group expects to have the study report ready by end of 2010 and to submit the application for marketing authorization early next year.

About Peripheral Arterial Diseases (PAD) and Intermittent Claudication

Peripheral arterial disease (PAD) is a common circulatory problem in which narrowed arteries reduce blood flow in the limbs. PAD can build up over a lifetime, and the symptoms may not become obvious until later in life. For many people, the outward symptoms of

FOR IMMEDIATE RELEASE

peripheral artery disease will not appear until the artery has narrowed by 60 percent or more.

The first noticeable symptom of peripheral artery disease may be **intermittent claudication** -- leg discomfort, pain or cramping that develops with activity, is relieved with rest, and recurs upon resuming activity. Intermittent claudication symptoms may also include numbness, weakness, heaviness or fatigue in the leg muscles when walking that are relieved at rest.

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 15 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets six products. Leespharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 20 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

About Sigma-Tau

Sigma-tau is one of the most important Italian pharmaceutical groups, which, with an excellent role internationally and a workforce of 2,439 achieved a corporate turnover of about € 615 million in 2009. The sigma-tau complex in Pomezia, the site of the Group's head office, houses not only the main factory, but also Avantgarde, a company operating in the pharmaceutical field and specializing in dermatology and gynaecology. Ever since its foundation in 1957, sigma-tau has based the various stages of its development on a single common denominator: research. The company's primacy in this field is an indispensable part of its corporate philosophy. A tangible impact on the quality of life can only be attained through constant, top-level research. Sigma-tau employs about 400 researchers, providing them with the means and resources to develop the therapeutic breakthroughs needed to guarantee better health conditions for everyone. For further information about Sigma-Tau: Website: www.sigma-tau.it

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.



FOR IMMEDIATE RELEASE

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com